Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 16, 2013New England Journal of Medicine

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

View Full Paper
Ask AI
Bookmark
Share

Authors

Daniel D. Von HoffDaniel D. Von HoffTranslational Genomics Research InstituteTEThomas J. ErvinBayfront Medical CenterFAFrancis P. ArenaMemorial Sloan Kettering Cancer Center

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Hoff et al. (2013) studied this question.

synapsesocial.com/papers/69d6ca51639f29d8dcab3326https://doi.org/10.1056/nejmoa1304369
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group2007 · 3,889 citations
  2. 2Irinotecan Plus Gemcitabine Results in No Survival Advantage Compared With Gemcitabine Monotherapy in Patients With Locally Advanced or Metastatic Pancreatic Cancer Despite Increased Tumor Response Rate2004 · 588 citations
  3. 3Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S02052010 · 632 citations
  4. 4Randomized Phase III Study of Exatecan and Gemcitabine Compared With Gemcitabine Alone in Untreated Advanced Pancreatic Cancer2006 · 279 citations
  5. 5Carbohydrate antigen 19‐9 change during chemotherapy for advanced pancreatic adenocarcinoma2009 · 122 citations